Devonian Health Group Inc. reported a net loss of $1.9 million for the quarter ended April 30, 2026, an improvement from the previous year's loss due to reduced impairment charges. The company remains debt-free with $0.7 million in cash and is focusing on developing its Thykamine™ drug for radiodermatitis prevention and atopic dermatitis treatment in children. Devonian is also exploring Thykamine™'s potential for metabolic and fibrotic diseases, aiming to advance its clinical pipeline despite ongoing losses.
Plum Acquisition Corp. IV has postponed its extraordinary general meeting of shareholders from July 2 to July 10, 2026, to allow more time for shareholder engagement. Consequently, the deadline for shareholders to submit redemption requests has been ...
The U.S. Supreme Court ruled in Chatrie v. U.S. that government collection of location data via geofence warrants constitutes a search under the Fourth Amendment. This decision overturns a lower court ruling and requires further review of whether the...
Mama’s Creations, a leading maker of fresh deli foods, announced a $100 million public offering of 5,555,556 shares at $18 each, with an option for underwriters to buy an additional 833,333 shares. The offering is expected to close on July 1, 2026, a...
Circle has burned $250 million USDC on Ethereum and minted $910 million on Solana, effectively moving $660 million in liquidity toward Solana. This move is part of a broader trend in 2026 where Circle is expanding USDC supply on Solana, driven by inc...
Synapse (SYN) token surged 13% recently, driven by large purchases from prominent investors like Arthur Hayes and interest in its options platform, Hypercall. Hayes views SYN as undervalued compared to traditional options markets, fueling bullish sen...
